http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Esperion to Present at the Jefferies 2017 Global Healthcare Conference
-
Esperion (ESPR) Comments on Report Containing 'Inaccurate Information'
-
Esperion Provides Update on Common Stock Trading Activity
-
Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference
-
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Esperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2017 Healthcare Conference
-
Esperion Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2017 Financial Results
-
Esperion to Participate in Fireside Chat at the 16th Annual Needham Healthcare Conference
-
Esperion Therapeutics (ESPR) Says FDA Confirms LDL-C Lowering Indication for Bempedoic
-
Esperion Announces FDA Confirmation Regarding Regulatory Pathway to Approval for an LDL-C Lowering Indication for Bempedoic Acid
-
Esperion Announces Initiation of Phase 2 Triplet Oral Therapy Study of Bempedoic Acid/Ezetimibe/Atorvastatin
-
Esperion Therapeutics (ESPR) Mendelian Randomization Study Results to Be Presented at ACC
-
Esperion Announces Oral Presentation on Genetic Validation of ATP Citrate Lyase Inhibition at the American College of Cardiology 66th Annual Scientific Session
-
Esperion Provides Bempedoic Acid Development Program Update; Reports Fourth Quarter and Full Year 2016 Financial Results
-
Esperion to Participate in Fireside Chat at RBC Capital Markets Global Healthcare Conference
-
Esperion Therapeutics (ESPR) Completes Enrollment of Pivotal Phase 3 Long-Term Safety and Tolerability Study of Bempedoic Acid
-
Esperion Completes Enrollment of Pivotal Phase 3 Long-Term Safety and Tolerability Study of Bempedoic Acid in Patients with Hypercholesterolemia
-
Esperion Therapeutics (ESPR) Initiates CVOT Trial for Bempedoic Acid
-
Esperion Announces Initiation of Global Cardiovascular Outcomes Trial for Bempedoic Acid
-
Esperion Announces Initiation of Three Pivotal Phase 3 Studies for Bempedoic Acid
-
Esperion to Present at the 35th Annual J.P. Morgan Healthcare Conference
-
Esperion Therapeutics (ESPR) Announces Publication of Bempedoic Acid Data in LDL-C
-
Esperion Therapeutics Announces Publication of Definitive Paper on Bempedoic Acid Mechanism of Action in Nature Communications
-
Esperion Therapeutics to Present at the Stifel 2016 Healthcare Conference
-
Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Third Quarter 2016 Financial Results
-
Esperion Therapeutics to Present at the Credit Suisse 25th Annual Healthcare Conference
-
Streetinsider.com's Hot Lunchtime Reads 10/13: (TWTR) (ESPR) (SSYS) (APTO)
-
Esperion Therapeutics (ESPR) Says Pivotal Phase 3 LDL-C to Include Patients on Any Statin, at Any Dose
-
Bempedoic Acid Global Phase 3 Clinical Program to Include Patients on Any Statin at Any Dose
-
Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Second Quarter 2016 Financial Results
-
Esperion Therapeutics (ESPR) Provides Update on Bempedoic Acid; FDA Says Regulatory Pathway for LDL-C Lowering Indication Not Well Defined
-
Esperion Therapeutics Provides Clinical Development and Regulatory Update for Bempedoic Acid
-
Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2016 Financial Results
-
Esperion Therapeutics to Present at the Barclays Global Healthcare Conference
-
Esperion Therapeutics Provides Bempedoic Acid Development Program Update; Reports Fourth Quarter and Full Year 2015 Financial Results
-
Esperion Therapeutics to Present at the 2016 RBC Capital Markets Global Healthcare Conference
-
Stocks Close Down But Not Before Rip Your Face Off Rally in Beaten Down Names
-
SHAREHOLDER NOTICE: Goldberg Law PC Announces an Investigation of Claims Against Esperion Therapeutics, Inc. and Advises Investors With Losses in Excess of $100,000 to Contact the Firm
-
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims against Esperion Therapeutics, Inc. and Advises Investors with Losses in Excess of $100,000 to Contact the Firm
-
Esperion Therapeutics (ESPR) Commences Bempedoic Acid Phase 3 in Certain Hyperlipidemia
-
Esperion Therapeutics Announces Initiation of Phase 3 Clinical Program With Long-Term Safety and Tolerability Study
-
Esperion Therapeutics Announces Initiation of Phase 2 Clinical Study of Bempedoic Acid in Patients Treated With High-Dose Statin Therapy
-
Esperion Therapeutics to Present at 34th Annual J.P. Morgan Healthcare Conference
-
Esperion Therapeutics to Present at November Healthcare Conferences
-
Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Third Quarter 2015 Financial Results
-
Esperion Therapeutics Announces Two Oral Presentations for ETC-1002 at the American Heart Association Scientific Sessions 2015
-
Pre-Open Stock Movers 10/12: (ESPR) (OREX) (EMC) Higher; (MHR) (SIEN) (LLY) Lower (more...)
-
Esperion Therapeutics Provides Further Updates on ETC-1002 Global Phase 3 Strategy Following Receipt of End-of-Phase 2 Meeting Minutes
-
Esperion Therapeutics Provides Update on the ETC-1002 Development Program Following End-of-Phase 2 Meeting With FDA
-
Pre-Open Stock Movers 08/10: (AQXP) (VLTC) (INO) (PCP) Higher; (SYN) (JD) (FCX) Lower (more...)

